/
Metabolic & Endocrine
Type 1 Diabetes Mellitus
30
Pipeline Programs↗
44
Active Trials↗
39
Companies Involved↗
Type 1 Diabetes Mellitus is an emerging landscape with 30 programs across 39 companies. The most active players are Sanofi, Pfizer, Eli Lilly. 4 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical16
Phase 13
Phase 27
Approved
No programs
Analysis
Modality Breakdown
93%
Small molecule
25 of 27 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 27 classified programs, each share of the total. Modality classified for 93% of 30 pipeline programs.
Analysis
Trial Status
239
clinical trials
Completed161 · 67%
Recruiting23 · 10%
Terminated15 · 6%
Unknown status11 · 5%
Active, not recruiting10 · 4%
Not yet recruiting9 · 4%
Other10 · 4%
Clinical Trials
Trial Activity
239 trials
Faecal Autologous Capsule Transplantation for Type 1 Diabetes Mellitus
Recruiting·—·Phase 2·NCT07083882·110 enrolled
Type 1 Diabetes Extension Study
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT02734277·111 enrolled
Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus
Recruiting·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT07142252·66 enrolled
Page 1 of 16
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)